Divestment of Crestor in Europe to Grünenthal completed
10 February 2021 07:00 GMT Divestment of Crestor in Europe to Grünenthal completed AstraZeneca has completed the divestment of the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe to Grünenthal GmbH (Grünenthal). Rights in the UK and Spain were not included in the agreement. Financial considerations Under the terms